Diana Mansour
ORCID: 0000-0003-1283-1365
· 7 papers in corpus
review
2022
Bleeding irregularities are one of the major reasons for discontinuation of oral contraceptives (OCs), and therefore clinicians need to set expectations during consultations. In this review we provide an overview of bleeding data of recentl…
review
2021
INTRODUCTION: Up to one-third of women of reproductive age experience heavy menstrual bleeding (HMB). HMB can give rise to iron deficiency (ID) and, in severe cases, iron-deficiency anemia (IDA). AIM: To review current guidelines for the m…
other
2012
More than 794 000 prescriptions are written for therapeutic (as opposed to contraceptive) use of norethisterone (or its synonym norethindrone) in the UK each year (data on file, Bayer plc). Although its licensed indications include “metropa…
rct
2009
BACKGROUND: This study compared the bleeding pattern, cycle control and safety of an oral contraceptive (OC) comprising estradiol valerate/dienogest (E2V/DNG; administered using a dynamic dosing regimen) with a monophasic OC containing ethi…
review
2009
Abstract Qlaira is a new multiphasic COC that is taken continuously and comprises four combinations of estradiol valerate and the progestogen dienogest, plus two inert tablets. In our New products review, Steve Chaplin presents the clinical…
review
2007
Since its launch, more than 9 million women worldwide have used the levonorgestrel intra-uterine system (IUS) for contraception, as a treatment for heavy menstrual bleeding and as the progestogen component of hormone-replacement therapy. Fo…
2006